drugset / Trial / NCT04344717

Pharmacokinetics of Apixaban in Patients With Short Bowel Syndrome Requiring Long Term Parenteral Nutrition

NCT04344717

Phase 4 Unknown 84 enrolled Universitaire Ziekenhuizen KU Leuven
Non-randomizedCrossoverOpen-labelTreatment

Summary

Short bowel syndrome (SBS) is defined as a loss of function of the small intestine resulting in a malabsorptive disorder. In SBS, oral drug absorption may be altered due to extensive intestinal resection. It remains unclear to what extent apixaban exposure is impacted in SBS.Therefore this study tries to investigate the pharmacokinetics (PK) of apixaban in adult patients with SBS requiring long-term parenteral nutrition (PN).

Timeline

Start
2020-12-20
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 2.5 mg
Subject Apixaban Small molecule 5 mg

Indications